OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Carotid Arteriosclerosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,011 reports · 55 co-occurring drugs

As of the last recalculation, Carotid Arteriosclerosis appears in 1,011 FAERS reports alongside 55 co-occurring drug terms. The strongest observed disproportionality signal is TELMISARTAN (PRR 58.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Telmisartan4858.158.2
Doxazosin Mesylate8754.254.3
Amphotericin B2847.347.4
Doxazosin6046.947.0
Valganciclovir3539.639.6
Valganciclovir Hydrochloride3539.639.6
Esomeprazole Magnesium Capsule, Delayed Release2434.934.9
Esomeprazole Magnesium Delayed Release Capsules2434.934.9
Esomeprazole Magnesium Dihydrate2434.734.8
Tamsulosin Hydrochloride3334.434.4
Sodium Bicarbonate3734.034.0
Sodium Bicarbonate Injection,3734.034.0
Candesartan Cilexetil3830.930.9
Torsemide4428.528.6
Calcitriol Capsules 0.25 Mcg2728.528.5
Calcitriol Capsules 0.5 Mcg2728.528.5
Calcitriol2728.128.2
Linagliptin2427.727.8
Indapamide2327.027.0
Nilotinib3726.826.8
Rosuvastatin Calcium3526.526.5
Valsartan Oral5421.621.6
Bisoprolol Fumarate12321.121.1
Mycophenolic Acid2919.219.2
Imatinib1619.019.0
Dapagliflozin2818.818.8
Candesartan3118.418.4
Clopidogrel Bisulfate8117.617.7
Insulin Degludec1917.017.0
Esomeprazole4716.316.3
Rosuvastatin13916.116.1
Fondaparinux Sodium615.315.4
Amlodipine Besylate And Valsartan815.015.0
Darbepoetin Alfa3614.214.2
Irbesartan3014.214.2
Ezetimibe4914.114.1
Rabeprazole Sodium1813.813.8
Clopidogrel11513.413.4
Nebivolol1013.013.1
Inclisiran512.912.9
Carvedilol7712.612.6
Minoxidil Foam 5% (Womens)1912.112.1
Bosutinib511.511.5
Mepolizumab2510.610.6
Empagliflozin319.79.8
Bendamustine Hcl79.49.4
Minoxidil198.98.9
Tafamidis58.88.8
Avapritinib58.58.5
Prasugrel Hydrochloride48.18.1
Liraglutide187.67.6
Apalutamide35.35.3
Ranibizumab64.74.7
Romosozumab-Aqqg34.64.6
Evolocumab293.83.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.